Effect of ketoconazole (KET) on the pharmacokinetics (PK) of atrasentan (ABT-627, ATN)
T Zhu, A Andre, I Facey, W Chiu, P Wang… - Journal of Clinical …, 2004 - ascopubs.org
4727 Background: ATN is an oral selective endothelin A receptor antagonist, currently in
phase 3 clinical development for the treatment of hormone-refractory prostate cancer. In …
phase 3 clinical development for the treatment of hormone-refractory prostate cancer. In …
Absolute bioavailability and regional absorption of ticagrelor in healthy volunteers
R Teng, J Maya - Journal of drug assessment, 2014 - Taylor & Francis
Objective: Ticagrelor is a direct-acting, reversibly-binding, oral P2Y12 receptor antagonist. It
demonstrates predictable, linear pharmacokinetics. Two studies were undertaken to further …
demonstrates predictable, linear pharmacokinetics. Two studies were undertaken to further …
Evaluation of patient/caregiver and healthcare provider knowledge, attitudes and behavior for safety and use of pexidartinib
M Salas, M Julian, Y Choi, Z Islam… - Journal of …, 2021 - becarispublishing.com
Aim: Pexidartinib was approved for the treatment of tenosynovial giant cell tumors with a
required Risk Evaluation and Mitigation Strategy (REMS) to ensure its safe use. As required …
required Risk Evaluation and Mitigation Strategy (REMS) to ensure its safe use. As required …
Mass Balance, Metabolic Pathways, Absolute Bioavailability, And Pharmacokinetics of Giredestrant In Healthy Subjects
S Kshirsagar, YC Chen, J Yu… - Drug Metabolism …, 2024 - dmd.aspetjournals.org
Giredestrant is a potent and selective small-molecule estrogen receptor degrader. The
objectives of this study were to assess the absolute bioavailability (aBA) of giredestrant and …
objectives of this study were to assess the absolute bioavailability (aBA) of giredestrant and …
[HTML][HTML] Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study
W Xiong, O Papasouliotis, EN Jonsson… - Cancer Chemotherapy …, 2022 - Springer
Purpose Tepotinib is a highly selective, potent, mesenchymal–epithelial transition factor
(MET) inhibitor, approved for the treatment of non-small cell lung cancer (NSCLC) harboring …
(MET) inhibitor, approved for the treatment of non-small cell lung cancer (NSCLC) harboring …
A phase Ib study of pexidartinib (PLX3397) and weekly paclitaxel in patients with advanced solid tumors including an ovarian cancer subset
R Wesolowski, N Sharma, B West… - Gynecologic …, 2016 - gynecologiconcology-online.net
Objectives: Colony-stimulating factor 1 signals through its transmembrane tyrosine kinase
receptor (CSF1R) to control the number and phenotype of tumor-associated macrophages …
receptor (CSF1R) to control the number and phenotype of tumor-associated macrophages …
PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co‐Administered with CYP3A4 Inhibitors
Physiologically based pharmacokinetic (PBPK) models of entrectinib and its equipotent
metabolite, M5, were established in healthy adult subjects and extrapolated to pediatric …
metabolite, M5, were established in healthy adult subjects and extrapolated to pediatric …
Prediction of Drug–Drug Interactions with Ensartinib as a Time-Dependent CYP3A Inhibitor Using Physiologically Based Pharmacokinetic Model
Ensartinib (X-396) is a second-generation anaplastic lymphoma kinase (ALK) tyrosine
kinase inhibitor (TKI) indicated for the treatment of ALK-positive patients with locally …
kinase inhibitor (TKI) indicated for the treatment of ALK-positive patients with locally …
Clinical confirmation that the selective JAK1 inhibitor filgotinib (GLPG0634) has a low liability for drug-drug interactions
F Namour, J Desrivot, A Van der Aa… - Drug metabolism …, 2016 - ingentaconnect.com
Objective: The selective Janus kinase 1 inhibitor filgotinib (GLPG0634), which is currently in
clinical development for the treatment of rheumatoid arthritis (RA) and Crohn's disease …
clinical development for the treatment of rheumatoid arthritis (RA) and Crohn's disease …
The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite
ME Dowty, R Qiu, A Dantonio, M Niosi, A Doran… - Drug Metabolism and …, 2024 - ASPET
Brepocitinib is an oral once-daily Janus kinase 1 and Tyrosine kinase 2 selective inhibitor
currently in development for the treatment of several autoimmune disorders. Mass balance …
currently in development for the treatment of several autoimmune disorders. Mass balance …